Vivex Biomedical’s Success Story Explored

SEBIO 2019 > 2019 News > Vivex Biomedical’s Success Story Explored


Vivex Biomedical’s Success Story Explored

October 15, 2019 | 2019 News

Please join us on Thursday, November 7, at 3:00 PM at the 21st Annual Southeast BIO
Investor & Partnering Forum for a fire-side chat on the emergence, funding, and growth of
Vivex Biomedical with “Vivex Biomedical: Tissue-Derived Biologic Therapies.”

Tom Callaway, venture partner at HealthQuest Capital, will interview the senior leadership that
built this Fort Lauderdale-based success. Panelists will include Vivex Founder Tracy S.
Anderson who is an Atlanta-based serial entrepreneur, John A. McCallum of private equity firm
JAM Capital and Chairman of the Board of Directors, and newly appointed Vivex CEO Peter
Wehrly who previously launched InfuseTM Bone Graft, the world’s first orthobiologic when he led
Medtronic Spine and Biologics businesses.

Vivex Biomedical Inc. is a leading regenerative medicine company, dedicated to creating new
standards in patient care. Founded in 2013 by Anderson, Vivex strives to create treatment
options and solutions that will improve clinical, surgical, and therapeutic patient care through
innovation. Vivex acquired the University of Miami Tissue Bank (UMTB) in 2014, a worldwide
leader in bone transplantation and tissue-based technology. Together, Vivex and UMTB have
distributed more than 2 million tissue allografts to 18 countries worldwide to better serve the
needs of patients.

Vivex is also in the pre-launch phase for VIA Disc, a novel product targeted at the treatment of
degenerative disc disease (DDD). VIA Disc is a tissue allograft and cellular therapy that is aimed
at improving pain and mobility for patients suffering from DDD.